Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib and Irinotecan in 2nd-line ESCC
NCT03251417Phase 2Terminated
- Sponsor
- Peking University
- Start
- Sep 2017
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Rivoceranib in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Peking University. Primary endpoint: Disease Control Rate at 3 months. Started Sep 2017; status: terminated.
02
Drugs
Rivoceranib
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT03251417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03251417.